|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCZ1B |
Gene summary for CCZ1B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCZ1B | Gene ID | 221960 |
| Gene name | CCZ1 homolog B, vacuolar protein trafficking and biogenesis associated | |
| Gene Alias | C7orf28A | |
| Cytomap | 7p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P86790 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 221960 | CCZ1B | HCC1_Meng | Human | Liver | HCC | 5.03e-05 | -2.93e-02 | 0.0246 |
| 221960 | CCZ1B | HCC2 | Human | Liver | HCC | 1.50e-08 | 1.30e+00 | 0.5341 |
| 221960 | CCZ1B | S014 | Human | Liver | HCC | 1.15e-04 | 1.82e-01 | 0.2254 |
| 221960 | CCZ1B | S027 | Human | Liver | HCC | 1.32e-07 | 5.09e-01 | 0.2446 |
| 221960 | CCZ1B | S028 | Human | Liver | HCC | 2.44e-14 | 4.58e-01 | 0.2503 |
| 221960 | CCZ1B | S029 | Human | Liver | HCC | 2.46e-15 | 6.56e-01 | 0.2581 |
| 221960 | CCZ1B | C04 | Human | Oral cavity | OSCC | 1.13e-06 | 4.00e-01 | 0.2633 |
| 221960 | CCZ1B | C08 | Human | Oral cavity | OSCC | 2.46e-25 | 6.49e-01 | 0.1919 |
| 221960 | CCZ1B | LN38 | Human | Oral cavity | OSCC | 4.85e-04 | 5.52e-01 | 0.168 |
| 221960 | CCZ1B | PTC01 | Human | Thyroid | PTC | 2.36e-11 | 9.05e-02 | 0.1899 |
| 221960 | CCZ1B | PTC04 | Human | Thyroid | PTC | 3.79e-07 | 7.35e-02 | 0.1927 |
| 221960 | CCZ1B | PTC05 | Human | Thyroid | PTC | 4.82e-08 | 1.84e-01 | 0.2065 |
| 221960 | CCZ1B | PTC06 | Human | Thyroid | PTC | 3.61e-12 | 1.64e-01 | 0.2057 |
| 221960 | CCZ1B | PTC07 | Human | Thyroid | PTC | 2.47e-20 | 1.29e-01 | 0.2044 |
| 221960 | CCZ1B | ATC09 | Human | Thyroid | ATC | 2.57e-02 | 1.50e-01 | 0.2871 |
| 221960 | CCZ1B | ATC11 | Human | Thyroid | ATC | 8.86e-04 | 3.29e-01 | 0.3386 |
| 221960 | CCZ1B | ATC12 | Human | Thyroid | ATC | 6.12e-07 | 2.34e-02 | 0.34 |
| 221960 | CCZ1B | ATC13 | Human | Thyroid | ATC | 1.54e-13 | 1.94e-01 | 0.34 |
| 221960 | CCZ1B | ATC1 | Human | Thyroid | ATC | 6.14e-03 | 1.81e-01 | 0.2878 |
| 221960 | CCZ1B | ATC2 | Human | Thyroid | ATC | 1.19e-19 | 1.07e+00 | 0.34 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCZ1B | SNV | Missense_Mutation | novel | c.166A>C | p.Asn56His | p.N56H | P86790 | protein_coding | deleterious(0) | probably_damaging(0.979) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CCZ1B | SNV | Missense_Mutation | novel | c.362T>C | p.Val121Ala | p.V121A | P86790 | protein_coding | tolerated(0.06) | benign(0.119) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCZ1B | SNV | Missense_Mutation | novel | c.554N>G | p.Asp185Gly | p.D185G | P86790 | protein_coding | deleterious(0.01) | possibly_damaging(0.774) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| CCZ1B | SNV | Missense_Mutation | c.562N>T | p.Asp188Tyr | p.D188Y | P86790 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CCZ1B | SNV | Missense_Mutation | c.725G>T | p.Arg242Ile | p.R242I | P86790 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CCZ1B | SNV | Missense_Mutation | rs373823879 | c.997N>T | p.His333Tyr | p.H333Y | P86790 | protein_coding | deleterious(0.03) | benign(0.036) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CCZ1B | SNV | Missense_Mutation | rs748215927 | c.988N>A | p.Ala330Thr | p.A330T | P86790 | protein_coding | tolerated(0.4) | benign(0.011) | TCGA-AG-3892-01 | Colorectum | rectum adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCZ1B | SNV | Missense_Mutation | c.847C>A | p.Leu283Ile | p.L283I | P86790 | protein_coding | tolerated(0.74) | benign(0.216) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CCZ1B | SNV | Missense_Mutation | rs764721779 | c.772G>A | p.Glu258Lys | p.E258K | P86790 | protein_coding | deleterious(0.01) | benign(0.302) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CCZ1B | SNV | Missense_Mutation | novel | c.486G>T | p.Lys162Asn | p.K162N | P86790 | protein_coding | tolerated(0.29) | benign(0.012) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |